Antimicrobial resistance (AMR) presents a critical challenge, surpassing deaths from HIV and malaria, with a forecast of 10 million annual deaths by 2050. Intensified by the COVID-19 pandemic and the prevalence of biofilm-associated, drug-resistant bacteria, this crisis has become a focal point for health research. Government strategies are increasingly focusing on substantial investments and novel funding models. Meanwhile, academic institutions and small research private entities are emerging as significant players in developing antimicrobial solutions with higher efficacy, reflecting a diversified approach to combating this escalating threat. In this era, where AMR poses a severe threat, discovering new antimicrobials is crucial. Recent studies have highlighted the potential of marine environments as a rich source of novel antimicrobial agents. However, despite these promising findings, there remains a significant gap in fully understanding and harnessing the potential of marine-derived compounds, necessitating further investigation.
This research topic aims to delve into the marine environment, a rich source of biodiversity, for novel antimicrobial agents. It focuses on the unique secondary metabolites produced by marine organisms like bacteria, fungi, sponges, tunicates, and algae. These compounds, with their distinct chemical structures and action mechanisms, are key to developing groundbreaking drugs.
Our goal is to identify, characterize, and explore the potential of these marine-derived antimicrobials, particularly in combating multidrug-resistant pathogens. By addressing these objectives, we aim to contribute to the development of new, effective antimicrobial therapies that can overcome the limitations of current treatments and provide a robust defense against AMR.
To gather further insights into the vast chemical diversity of marine-derived antimicrobials, we welcome articles addressing, but not limited to, the following sub-topics:
- Isolation, purification, and structural analysis of new marine-derived compounds
- Advanced bioassays and screening techniques for antimicrobial activity
- Omics approaches, databases, and bioinformatics in the discovery process
- Chemo- and biosynthesis of marine-derived antimicrobial agents
- Mechanisms of action and interactions with microbial targets
- Overcoming resistance mechanisms in pathogens
- Pharmacokinetics and in vivo efficacy of marine-derived antimicrobials
- Sustainable sourcing and ecological impacts of marine-derived compounds
- Reviews and perspectives on the clinical potential of marine antimicrobials
- Comparison of marine-derived antimicrobials with existing antibiotics
- Insights into clinical trial strategies for marine-derived antimicrobial agents
We invite a broad range of contributions from marine biology to clinical research, aiming to bridge the gap between discovery and practical application in combating AMR.
We welcome all article types allowed in the Antimicrobials, Resistance and Chemotherapy and Marine Biotechnology and Bioproducts sections.
Antimicrobial resistance (AMR) presents a critical challenge, surpassing deaths from HIV and malaria, with a forecast of 10 million annual deaths by 2050. Intensified by the COVID-19 pandemic and the prevalence of biofilm-associated, drug-resistant bacteria, this crisis has become a focal point for health research. Government strategies are increasingly focusing on substantial investments and novel funding models. Meanwhile, academic institutions and small research private entities are emerging as significant players in developing antimicrobial solutions with higher efficacy, reflecting a diversified approach to combating this escalating threat. In this era, where AMR poses a severe threat, discovering new antimicrobials is crucial. Recent studies have highlighted the potential of marine environments as a rich source of novel antimicrobial agents. However, despite these promising findings, there remains a significant gap in fully understanding and harnessing the potential of marine-derived compounds, necessitating further investigation.
This research topic aims to delve into the marine environment, a rich source of biodiversity, for novel antimicrobial agents. It focuses on the unique secondary metabolites produced by marine organisms like bacteria, fungi, sponges, tunicates, and algae. These compounds, with their distinct chemical structures and action mechanisms, are key to developing groundbreaking drugs.
Our goal is to identify, characterize, and explore the potential of these marine-derived antimicrobials, particularly in combating multidrug-resistant pathogens. By addressing these objectives, we aim to contribute to the development of new, effective antimicrobial therapies that can overcome the limitations of current treatments and provide a robust defense against AMR.
To gather further insights into the vast chemical diversity of marine-derived antimicrobials, we welcome articles addressing, but not limited to, the following sub-topics:
- Isolation, purification, and structural analysis of new marine-derived compounds
- Advanced bioassays and screening techniques for antimicrobial activity
- Omics approaches, databases, and bioinformatics in the discovery process
- Chemo- and biosynthesis of marine-derived antimicrobial agents
- Mechanisms of action and interactions with microbial targets
- Overcoming resistance mechanisms in pathogens
- Pharmacokinetics and in vivo efficacy of marine-derived antimicrobials
- Sustainable sourcing and ecological impacts of marine-derived compounds
- Reviews and perspectives on the clinical potential of marine antimicrobials
- Comparison of marine-derived antimicrobials with existing antibiotics
- Insights into clinical trial strategies for marine-derived antimicrobial agents
We invite a broad range of contributions from marine biology to clinical research, aiming to bridge the gap between discovery and practical application in combating AMR.
We welcome all article types allowed in the Antimicrobials, Resistance and Chemotherapy and Marine Biotechnology and Bioproducts sections.
